New hope for hodgkin lymphoma patients who Can't get transplants
NCT ID NCT06393361
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of drugs (Chidamide, Decitabine, and an anti-PD-1 antibody) for people with classical Hodgkin lymphoma that has come back or not responded to treatment, and who cannot or choose not to have a stem cell transplant. The goal is to see if this combo helps keep the cancer from growing for at least a year. About 100 adults aged 18 to 75 will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INELIGIBLE OR REFUSED TRANSPLANT PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital
RECRUITINGBeijing, 100853, China